ProCE Banner Activity


Research Platform Presentations 2021


Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: November 06, 2022

Expiration: November 06, 2024


Additional Information

Program Medium

This program has been made available online.

A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) 

 View more SIDPEC Activities ?

NOTE: If you attended this live CE activity that was held on November 6, 2021 at the SIDP Annual Meeting AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-21-273-L01-P), you are NOT eligible to also receive CE credit for this home-study activity.


These four projects represent some of the exceptional research being conducted by SIDP members. Presentations include the following: Antipseudomonal vs Narrow-spectrum Agents for the Treatment of Community-Onset Intra-abdominal Infections; Pharmacogenomic Testing Provides Insight and Enhances Medication Management in Persons Living with HIV (PWH); Immediate hypersensitivity to fluoroquinolones: a cohort assessing cross-reactivity; Current State of Infectious Diseases Pharmacist OPAT/COpAT Practice in the United States.

This is a featured CE activity on the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) website. SIDPEC is the educational hub of the Society of Infectious Diseases Pharmacists (SIDP). The SIDPEC portal provides educational activities on infectious disease pharmacotherapy for clinical pharmacists, health systems pharmacists, community pharmacists, and other allied health disciplines.

Learning Objectives

The target audience for this activity is pharmacists. At the completion of this activity, the participant will be able to:

  • Identify risk factors associated with 90-day post-infection complications for community acquired intra-abdominal infections.
  • Identify various activities performed by pharmacists with OPAT/COpAT responsibilities.
  • Recall the frequency of cross-reactivity between fluoroquinolones.
  • Identify drug – gene pairings for antiretroviral medications.


Lacy Worden, PharmD
PGY2 Infectious Diseases Pharmacy Resident
Mercy Health Saint Mary’s
Grand Rapids, MI

Christina (Rivera) O’Connor, PharmD, RPh, BCPS, AAHIV-P
Mayo Clinic – Rochester
Antimicrobial Stewardship Clinical Pharmacist Manager
Assistant Professor of Pharmacy
Mayo Clinic College of Medicine and Science

Jessica Wright, PharmD, RPh, BCACP
Mayo Clinic – Rochester
Pharmacogenomics Pharmacist
Center for Individualized Medicine
Instructor of Pharmacy
Mayo Clinic College of Medicine and Science

Sara F. Azimi, PharmD candidate
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado

Vincent Mainella, PharmD candidate
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado

Monica V. Mahoney, PharmD
Clinical Pharmacy Specialist, Infectious Diseases
Outpatient ID/OPAT Clinics
Beth Israel Deaconess Medical Center

The planners and content peer reviewers from ProCE, LLC and SIDP do not have any relevant financial relationships to disclose.


Release Date: November 6, 2021
Expiration Date: November 6, 2024


ACPE Logo This activity is jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-273-H01-P has been assigned to this home-study knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Statements of completion will be issued online at upon completion of the evaluation and post-test with a score of 70% or higher. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.


It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Lacy Worden, Christina O'Connor, Jessica Wright, Sara Azimi and Vincent Mainella have no relevant commercial or financial relationships to disclose. Monica Mahoney has received consulting fees and fees for non-CE Services from Cepheid, research and consulting fees from Merck, and consulting fees from Melinta, Paratek, Qpex, Spero and Tetraphase.


Provided by ProCE, LLC in partnership with the Society of Infectious Diseases Pharmacists (SIDP).

No external support has been received for this activity.

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.